SERVING OVERLOOKED PATIENTS

Serial Number 98212907
Registration 8061555
700

Registration Progress

Application Filed
Oct 6, 2023
Under Examination
Nov 12, 2024
Approved for Publication
Sep 17, 2024
Published for Opposition
Sep 17, 2024
Registered
Dec 9, 2025

Trademark Image

SERVING OVERLOOKED PATIENTS

Basic Information

Serial Number
98212907
Registration Number
8061555
Filing Date
October 6, 2023
Registration Date
December 9, 2025
Published for Opposition
September 17, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Dec 9, 2025
Registration
Registered
Classes
040 044

Rights Holder

Azurity Pharmaceuticals, Inc.

03
Address
8 Cabot Road, Suite 2000
Woburn, MA 01801

Ownership History

Azurity Pharmaceuticals, Inc.

Original Applicant
03
Woburn, MA

Azurity Pharmaceuticals, Inc.

Owner at Publication
03
Woburn, MA

Azurity Pharmaceuticals, Inc.

Original Registrant
03
Woburn, MA

Legal Representation

Attorney
Douglas R. Wolf

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

38 events
Date Code Type Description Documents
Dec 9, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Dec 9, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Nov 18, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Nov 18, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Oct 30, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 30, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 30, 2025 ALIE A ASSIGNED TO LIE Loading...
Oct 28, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Oct 6, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Oct 6, 2025 GNRT O NON-FINAL ACTION E-MAILED Loading...
Oct 6, 2025 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Sep 13, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 12, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Mar 7, 2025 IUAF S USE AMENDMENT FILED Loading...
Sep 12, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Apr 27, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Sep 12, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 28, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 7, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Nov 12, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 17, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 17, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 28, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 12, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Aug 9, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 9, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 9, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
May 24, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
May 24, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
May 24, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 7, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
May 7, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 7, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 22, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Feb 22, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Feb 22, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Feb 15, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 15, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...

Detailed Classifications

Class 040
Custom manufacture of reformulated pharmaceuticals in the field of cardiovascular, central nervous system, endocrine, gastro-intestinal, anti-infective and oncology medicines; custom reformulation of pharmaceuticals for easier patient delivery
First Use Anywhere: 20220400
First Use in Commerce: 20220400
Class 044
Providing information to patients in the fields of administering medication and how medicines are designed to bring patients new formulations and dosage innovations to help them benefit from existing medicines
First Use Anywhere: 20220400
First Use in Commerce: 20220400

Classification

International Classes
040 044